The elimination half-life of DP001 given orally to end-stage renal disease patients on hemodialysis is 51 h and is much longer than the clinically available vitamin D receptor agonists.

Compared to baseline, after 4 weeks of DP001, mean intact parathyroid hormone (iPTH) post-dose was suppressed 33% and no clinically significant changes in serum calcium, phosphorus, or calcium X phosphorus product were observed.

DP001 is a novel and potent vitamin D receptor analog that may represent a therapeutic improvement in the control of PTH suppression in hemodialysis patients due to its long half-life and tissue distribution.